Prognostic role of neutrophil-to-lymphocyte ratio in castration-resistant prostate cancer patients treated with docetaxel.

Pinar, Atike; Özveren, Ahmet; Surmeli, Zeki Gokhan; Şanlı, Ulus Ali; Uslu, Rüçhan; Karaca, Burçak

doi:10.1200/jco.2015.33.15_suppl.e16050

Search citation statements

Order By: Relevance

Paper Sections

Select...

Biomarkers Under Development and Evaluation1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2016

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nonetheless, TLRs now represent a promising therapeutic target. 178 The negative prognostic impact of a high neutrophilto-lymphocyte ratio in pre- 179 and postdocetaxel mCRPC patients 180 has also been documented. High neutrophilto-lymphocyte ratio also holds prognostic and predictive value in mCRPC patients during enzalutamide treatment.…”

Section: Biomarkers Under Development and Evaluationmentioning

confidence: 98%

The Present and Future of Biomarkers in Prostate Cancer: Proteomics, Genomics, and Immunology Advancements

Gaudreau

Stagg²,

Soulières

et al. 2016

Biomark�Cancer

View full text Add to dashboard Cite

Prostate cancer (PC) is the second most common form of cancer in men worldwide. Biomarkers have emerged as essential tools for treatment and assessment since the variability of disease behavior, the cost and diversity of treatments, and the related impairment of quality of life have given rise to a need for a personalized approach. High-throughput technology platforms in proteomics and genomics have accelerated the development of biomarkers. Furthermore, recent successes of several new agents in PC, including immunotherapy, have stimulated the search for predictors of response and resistance and have improved the understanding of the biological mechanisms at work. This review provides an overview of currently established biomarkers in PC, as well as a selection of the most promising biomarkers within these particular fields of development.

show abstract

Section: Biomarkers Under Development and Evaluationmentioning

confidence: 98%